Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells

EMBO Journal

Volumn 19, Issue 22, 2000, Pages 6051-6064

  Sengupta, Sagar ^a   Vonesch, Jean Luc ^a   Waltzinger, Caroline ^a   Zheng, Hong ^a   Wasylyk, Bohdan ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Apoptosis; Cell cycle; Cellular localization; GR antagonists; Neuroblastoma

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; STRESS; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL NUCLEUS; CYTOPLASM; DEXAMETHASONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROMOLECULAR SUBSTANCES; NEUROBLASTOMA; RECEPTOR CROSS-TALK; RECEPTORS, GLUCOCORTICOID; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034669037     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/19.22.6051     Document Type: Article

References (91)

1. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage
2. Stabilization of wild-type p53 by hypoxia-inducible factor 1α
3. Mdm2 expression is induced by wild-type p53 activity
4. Anti-inflammatory actions of steroids: Molecular mechanisms
5. RU 486 (mifepristone). A short overview of its mechanisms of action and clinical uses at the end of 1996
6. Steroid hormone receptors: Many actors in search of a plot
7. Physical and functional interaction between p53 and the Werner's syndrome protein
8. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization
9. p53 Gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma
10. A chimeric Cre recombinase inducible by synthetic, but not by natural ligands of the glucocorticoid receptor
11. Distinct TFIID complexes mediate the effect of different transcriptional activators
12. Radiation-induced cell cycle arrest compromised by p21 deficiency
13. p53 Suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor
14. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21(waf1/cip1) promoter in rat hepatoma cells
15. Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression
16. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
17. High-efficiency transformation of mammalian cells by plasmid DNA
18. Apoptosis and programmed cell death in immunity
19. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation
20. CTS1: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties
21. A new-dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death
22. Multiple epithelial cell-derived factors enhance neutrophil survival. Regulation by glucocorticoids and tumor necrosis factor-α
23. Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element
24. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene
25. p53 Plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells
26. WAF1, a potential mediator of p53 tumor suppression
27. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor
28. JNK targets p53 ubiquitination and degradation in non-stressed cells
29. A transcriptionally active DNA-binding site for human p53 protein complexes
30. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo
31. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
32. The complexity of p53 modulation: Emerging patterns from divergent signals
33. Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
34. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
35. Mdm2 promotes the rapid degradation of p53
36. Dexamethasone induced proliferation of cultured retinal pigment epithelial cells
37. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the 'hot spot' mutant phenotypes
38. p53 mutations in human cancers
39. RB regulates the stability and the apoptotic function of p53 via MDM2
40. Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2
41. Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells
42. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis
43. Mutagenesis of the glucocorticoid receptor in mice
44. p53: Puzzle and paradigm
45. Regulation of p53 stability by Mdm2
46. Functional domains of the human estrogen receptor
47. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53
48. p53, the cellular gatekeeper for growth and division
49. Enhanced proliferation of human fibroblasts, in the presence of dexamethasone, is accompanied by changes in p21(Waf1/Cip1/Sdi1) and the insulin-like growth factor type 1 receptor
50. p53 Is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily
51. Effects and metabolism of steroid hormones in human neuroblastoma cells
52. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein
53. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53
54. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor
55. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
56. Identification of a p53-dependent negative response element in the bcl-2 gene
57. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
58. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
59. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors
60. 1 checkpoint after DNA damage
61. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas
62. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
63. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
64. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide
65. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif
66. DNA binding of the glucocorticoid receptor is not essential for survival
67. Cellular physiology and molecular events in hypoxia-induced apoptosis
68. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells. SH-SY5Y, through a p53-dependent pathway
69. Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor
70. Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol
71. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor
72. Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53
73. Subcellular distribution of the p53 protein during the cell cycle of Ba1b/c 3T3 cells
74. The ARF/p53 pathway
75. c-Abl neutralizes the inhibitory effect of Mdm2 on p53
76. The p53 tumour suppressor gene
77. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
78. Genetic dissection of glucocorticoid receptor function in mice
79. Localization of the glucocorticoid receptor in discrete clusters in the cell nucleus
80. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
81. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
82. p53 Mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
83. Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone?
84. Inhibition by dexamethasone of transforming growth factor β1-induced apoptosis in rat hepatoma cells: A possible association with Bc1-xL induction
85. Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53
86. Modulation of hormone-dependent transcriptional activity of the glucocorticoid receptor by the tumor suppressor p53
87. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways
88. Identification and classification of p53-regulated genes
89. Cytoplasmically 'sequestered' wild type p53 protein is resistant to Mdm2-mediated degradation [published erratum appears in J. Biol. Chem., 275, 11538]
90. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
91. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein